Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’
INBS offers a patented, non-invasive testing solution positioned to disrupt a global drug screening market projected to reach $14.9 billion by 2030. The company is revenue-generating, with 148% year-over-year growth in FY 2024 and 450+ active customer accounts. Its Intelligent Fingerprinting system provides rapid, on-site results with a lower cost and higher convenience compared to traditional methods. The Intelligent Fingerprinting Drug Screening System is already in commercial use internationally, and a U.S. product launch is planned for 2025, with FDA 510(k) clearance in process and new patent protections underway. INBS is led by a seasoned executive team with global healthcare…
